Oxular
Oxular Limited is a UK-based clinical-stage biotechnology company developing proprietary ocular gene therapy delivery technology to treat inflammatory eye disorders including scleritis. The company was acquired by Regeneron Pharmaceuticals in January 2025.
- Company typePrivate
- Founded2014
- HeadquartersOxford, United Kingdom
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Oxular does
Oxular Limited is a UK-based clinical-stage biotechnology company founded in 2014 and headquartered in Oxford, United Kingdom, specializing in proprietary ocular gene therapy delivery technology for the treatment of eye disorders, with a particular focus on inflammatory conditions including scleritis. The company's core asset is a domain-specialized gene therapy delivery platform designed to enable targeted biologic and genetic medicine administration to ocular tissues, differentiating it from broader gene therapy developers through ocular-specific engineering. Its vertical segmentation is concentrated in ophthalmology and inflammatory eye disease, with no disclosed commercial products, pricing model, distribution channels, or marketing channels in the source data.
Oxular was financed through three venture rounds totaling approximately $76.7 million between 2016 and 2021, drawing institutional life-sciences investors including Forbion Capital Partners, IP Group, Imperial Innovations, Neomed Management, and V-Bio Ventures. Leadership included Mark Gaffney as Chief Executive Officer, co-founder Tom Cavanagh, and Ronald Yamamoto as Chief Scientific Officer, operating with an 11-50 employee footprint consistent with clinical-stage pipeline development. In January 2025, Oxular was wholly acquired by Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) for an undisclosed sum, with the stated strategic rationale of strengthening Regeneron's ocular gene therapy delivery capabilities. Following the transaction, Oxular operates as a wholly-owned subsidiary of Regeneron, and its independent operating status has ceased.
Oxular firmographics
Firmographics- Name
- Oxular
- Legal name
- Oxular Limited
- Website
- https://oxular.com
- Company type
- Private
- Founded year
- 2014
- Operating status
- Acquired
- Headcount range
- 11–50 employees
- Short description
- Oxular Limited is a UK-based clinical-stage biotechnology company developing proprietary ocular gene therapy delivery technology to treat inflammatory eye disorders including scleritis. The company was acquired by Regeneron Pharmaceuticals in January 2025.
- Ownership category
- akta.pro rank
Oxular industry classification
Industry- Product category
- Ophthalmic Drug Delivery Technology
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Gene Therapy Delivery Devices & Administration Systems (catheters, intrathecal, ocular delivery) (HLAAACAL)
- akta.pro secondary industry
- Ocular Drug Delivery Devices (Eye Droppers/Inserts) (HLAHAIAL)
Keywords
Where Oxular is headquartered
LocationHeadquarters
- HQ city
- Oxford
- HQ country
- United Kingdom
- HQ region
- Europe
Offices1 record
Markets served
Oxular business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations
Oxular product offering
Product offeringCore offering
Oxular develops a proprietary ocular gene therapy delivery technology platform designed for treating eye disorders, with specialization in inflammatory eye diseases such as scleritis. The UK-based medical device startup focuses on advancing biologic drug delivery systems targeted at ocular conditions.
Differentiator
Problem solved
Functional benefit
Products and services
- Ocular Gene Therapy Delivery Platform
Companies that use Oxular
Customer profileSegments1 record
Ideal customer profiles1 record
Oxular technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature1 record
Oxular partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Regeneron Pharmaceuticals Inc.coreIn January 2025, Regeneron Pharmaceuticals Inc. acquired UK-based Oxular Limited for an undisclosed sum. The acquisition was specifically aimed at strengthening Regeneron's ocular gene therapy delivery capabilities for treating eye disorders including scleritis. This represents a strategic acquisition to enhance Regeneron's ophthalmology portfolio through Oxular's specialized gene therapy delivery technology.
Recent moves3 records
Expansion highlights3 records
Oxular competitors and assessment
Company assessmentDirect peers
- Gyroscope Therapeutics: Develops gene therapies for ocular diseases, including delivery-focused approaches for retinal disorders. Directly comparable as an ocular gene therapy specialist acquired by a major pharma (Novartis).
- Adverum Biotechnologies: Clinical-stage gene therapy company developing novel gene therapy approaches for ocular diseases. Comparable as a competing ocular gene therapy delivery platform targeting inflammatory and retinal indications.
- Regenxbio: Clinical-stage biotech leveraging AAV-based gene therapy delivery platforms, with active ophthalmology programs. Comparable gene therapy delivery technology targeting eye disorders.
- MeiraGTx Holdings: Clinical-stage gene therapy company with a dedicated ophthalmology franchise developing gene therapies for inherited and acquired eye diseases. Comparable ocular gene therapy pipeline and delivery focus.
- EyePoint Pharmaceuticals: Specializes in sustained ocular drug delivery technologies, including the Durasert platform for posterior segment diseases. Comparable as an ocular drug delivery specialist targeting inflammatory eye conditions.
- Clearside Biomedical: Develops suprachoroidal drug delivery technology for ocular diseases including inflammatory conditions. Comparable as an ocular delivery platform addressing similar inflammatory eye indications.
Emerging players
- Applied Genetic Technologies Corp (AGTC): Clinical-stage gene therapy developer focused on rare inherited ophthalmic diseases. Comparable ocular gene therapy pipeline with delivery platform overlap, though narrower indication focus.
Broad incumbents
- Spark Therapeutics (Roche): Pioneer in gene therapy now part of Roche, with approved ophthalmology gene therapy (Luxturna). Comparable as an established ocular gene therapy player with validated delivery platform.
- Regeneron Pharmaceuticals: Top-tier biopharma with an active ophthalmology franchise (Eylea, aflibercept) and genetic medicines capabilities. Parent of Oxular and strategic acquirer, representing both a peer/partner and an incumbent in ocular therapeutics.
- Roche: Global biopharma with a major ophthalmology franchise (Lucentis, Susvimo) and gene therapy capabilities via Spark. Comparable broad incumbent in ocular therapeutics and genetic medicines.
Market position
Strengths3 records
Weaknesses3 records
Competitive moat3 records
Key risks5 records
Key highlights5 records
Customer concentration
Oxular social profiles
Digital presenceOxular financial estimates
Financial estimateRevenue estimate
Valuation estimate
Oxular leadership team
Management profileNumber of profiles
Profiles3 records
Oxular funding detail
Funding detailFunding overview
Funding rounds3 records
Investors6 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Oxular M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Oxular
What does Oxular do?
Oxular develops a proprietary ocular gene therapy delivery technology platform designed for treating eye disorders, with specialization in inflammatory eye diseases such as scleritis. The UK-based medical device startup focuses on advancing biologic drug delivery systems targeted at ocular conditions.
Is Oxular a public or private company?
Oxular is a private company. It is classified as corporate owned and is currently acquired.
When was Oxular founded?
Oxular was founded in 2014. It employs 11 to 50 people.
Where is Oxular based?
Oxular is headquartered in Oxford, United Kingdom, in the Europe region.
Who are Oxular's main competitors?
Direct peers on record are Gyroscope Therapeutics, Adverum Biotechnologies, Regenxbio, MeiraGTx Holdings, EyePoint Pharmaceuticals and Clearside Biomedical. Applied Genetic Technologies Corp (AGTC) is listed as an emerging player. Broad incumbents are Spark Therapeutics (Roche), Regeneron Pharmaceuticals and Roche.
Does Oxular have an API?
No public API is recorded for Oxular.
What industry is Oxular in?
Oxular's product category is Ophthalmic Drug Delivery Technology. Its primary akta.pro industry code is HLAAACAL, Gene Therapy Delivery Devices & Administration Systems (catheters, intrathecal, ocular delivery), with a secondary code of HLAHAIAL, Ocular Drug Delivery Devices (Eye Droppers/Inserts). Its NAICS code is 325414 and its SIC code is 2836.